Zobrazeno 1 - 5
of 5
pro vyhledávání: '"mk-7264"'
Autor:
Ahmed Abu-Zaid, Aseel Khalid Aljaili, Amnah Althaqib, Fatima Adem, Doaa Ali Alhalal, Amena Faiq Almubarak, Saud Musaab Aldughaither, Sarah Ali Alghabban, Ghaidaa Alfaraj, Ahmed Taher Masoud, Nujud Abdullah Alsuhaibani
Publikováno v:
Annals of Thoracic Medicine, Vol 16, Iss 2, Pp 127-140 (2021)
AIM: We conducted this systematic review and meta-analysis to investigate the efficacy and safety of gefapixant, a novel P2X3 receptor antagonist, in patients with chronic cough. METHODS: We searched four databases for randomized controlled trials (R
Externí odkaz:
https://doaj.org/article/9daaf442019a4a64b60ef0cca3a1d36e
Autor:
Fernando J, Martinez, Amna Sadaf, Afzal, Jaclyn A, Smith, Anthony P, Ford, Jerry Jing, Li, Yuping, Li, Michael M, Kitt, Murali, Ramaswamy
Publikováno v:
Pulmonary Therapy
Chronic Cough in IPF Study Group, Martinez, F J, Afzal, A S, Smith, J A, Ford, A P, Li, J J, Li, Y & Kitt, M M 2021, ' Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial ', Pulmonary therapy . https://doi.org/10.1007/s41030-021-00162-9
Chronic Cough in IPF Study Group, Martinez, F J, Afzal, A S, Smith, J A, Ford, A P, Li, J J, Li, Y & Kitt, M M 2021, ' Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial ', Pulmonary therapy . https://doi.org/10.1007/s41030-021-00162-9
Introduction Chronic cough is a highly problematic symptom for patients with idiopathic pulmonary fibrosis (IPF); limited therapeutic options are available. We evaluated gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough in IP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d58682a6e9f33e7a4abb1f43461f81e0
https://doi.org/10.1007/s41030-021-00162-9
https://doi.org/10.1007/s41030-021-00162-9
Autor:
Nujud Abdullah Alsuhaibani, Amnah Althaqib, Ahmed Taher Masoud, Amena Faiq Almubarak, Doaa Ali Alhalal, Ghaidaa A. Alfaraj, Ahmed Abu-Zaid, Aseel Khalid Aljaili, Fatima Adem, Sarah Ali Alghabban, Saud Musaab Aldughaither
Publikováno v:
Annals of Thoracic Medicine, Vol 16, Iss 2, Pp 127-140 (2021)
Annals of Thoracic Medicine
Annals of Thoracic Medicine
AIM: We conducted this systematic review and meta-analysis to investigate the efficacy and safety of gefapixant, a novel P2X3 receptor antagonist, in patients with chronic cough. METHODS: We searched four databases for randomized controlled trials (R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c4a8447066e2bc24d6291746364b44
http://www.thoracicmedicine.org/article.asp?issn=1817-1737
http://www.thoracicmedicine.org/article.asp?issn=1817-1737
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.